Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

NCT02076386 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT02076386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
Lead sponsor
ViiV Healthcare
Phase
Observational
Overall status
Completed
Start date
March 4, 2014
Completion date
July 5, 2017
Enrollment
411 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus